Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Conditions:   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Trametinib;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 28, 2020 / by / in
Comments